By Business Wire, September 26, 2013, 05:00:00 AM EDT
Scientific Journal Article Demonstrates Superiority of n3D's Bio-Assembler
NOKOMIS, Fla.--(BUSINESS WIRE)--
A recent study published in the scientific journal Biochimica et
Biophysica Acta provides an illuminating demonstration of the
superiority of three-dimensional cell cultures produced by Rainbow Coral
Corp. (OTCBB:RBCC) partner Nano3D Biosciences' technology over
traditional two-dimensional cultures.
Produced by researchers from Houston's Baylor College of Medicine and
the Methodist Hospital Research Institute, the study reports on
experiments into the transdifferentiation of vascular smooth muscle
cells into calcifying vascular cells. The group used n3D's Bio-Assembler
technology to magnetically levitate their cell cultures in order to
produce more lifelike tissues.
The study found that the cells grew more rapidly using in 3-D than 2-D,
and differentiated in days rather than weeks. The published piece is yet
more evidence to the scientific community that the Bio-Assembler is an
essential tool for all kinds of cellular research, including disease
"The Bio-Assembler represents a new evolution in cell culture
technology," said RBCC CEO Patrick Brown. "Thanks to high-profile
research being conducted using this system, word is being spread very
rapidly as to the unparalleled utility and efficiency afforded by the
RBCC formed a joint venture with n3D to market and develop the
Bio-Assembler last year. Rainbow Biosciences is dedicated to the
marketing and development of new medical and research technology
innovations designed to help capture a growing share of a booming
biotech industry alongside Bristol Myers Squibb Co. (NYSE:BMY), Biogen
Idec Inc. (NASDAQ:BIIB), Abbott Laboratories (NYSE:ABT) and Amgen Inc.
For more information on RBCC's partnership with n3D and other biotech
initiatives, please visit www.rainbowbiosciences.com/investors.html.
About Rainbow Biosciences
Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral
Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships
with biotechnology developers to deliver profitable new medical
technologies and innovations. For more information on our
growth-oriented business initiatives, please visit www.RainbowBioSciences.com.
For investment information and performance data on the Company, please
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words "believes," "expects,"
"anticipate" or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the Company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone's past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information
included herein for events occurring after the date hereof.
Source: Rainbow Coral Corp.